STOCK TITAN

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

Kiniksa Pharmaceuticals International (KNSA) management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 16, 2026.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Kiniksa Pharmaceuticals International (KNSA) management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 16, 2026.

The London session is scheduled for 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time). A live webcast will be available through the Investors section of Kiniksa’s website, with a replay available within approximately 48 hours after the event.

Loading...
Loading translation...

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time).

A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com


Keep reading